This article is a correction to:
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
Yixing Gao1
Bao Liu2,3
Lan Feng2,3Binda Sun2,3
Shu He2,3Yidong Yang2,3
Gang Wu2,3Guoji E2,3
Chang Liu2,3Yuqi Gao2,3
Erlong Zhang2,3*
Bo Zhu1*- 1Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, China
- 2Institute of Medicine and Equipment for High Altitude Region, College of High Altitude Military Medicine, Army Medical University, Chongqing, China
- 3Key Laboratory of High Altitude Medicine, People’s Liberation Army, Chongqing, China
A Corrigendum on
Targeting JUN, CEBPB, and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma
by Gao Y, Liu B, Feng L, Sun B, He S, Yang Y, Wu G, E G, Liu C, Gao Y, Zhang E and Zhu B (2019) Front. Oncol. 9:33. doi: 10.3389/fonc.2019.00033
In the published article, two Supplementary Figures were missing. We provide both the splicing data and the raw images of Figure 6B in Supplementary Figure 3. The Supplementary Figure 3 and caption have been added to the original article. Moreover, we have repeated the experiments of Figure 6B and provided the figure without splicing in Supplementary Figure 4. The Supplementary Figure 4 and caption have been added to the original article.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: glioblastoma, hypoxia, drug resistance, JUN, CEBPB, HDAC3
Citation: Gao Y, Liu B, Feng L, Sun B, He S, Yang Y, Wu G, E G, Liu C, Gao Y, Zhang E and Zhu B (2024) Corrigendum: Targeting JUN, CEBPB and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma. Front. Oncol. 14:1392899. doi: 10.3389/fonc.2024.1392899
Received: 28 February 2024; Accepted: 08 March 2024;
Published: 23 April 2024.
Edited and Reviewed by:
Sharon R Pine, University of Colorado Anschutz Medical Campus, United StatesCopyright © 2024 Gao, Liu, Feng, Sun, He, Yang, Wu, E, Liu, Gao, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bo Zhu, bo.zhu@tmmu.edu.cn; Erlong Zhang, loong0810@sina.com